Skip to content

Clinical Pearls of Early Use of Xanomeline–Trospium in the In-patient Setting with Michael Halassa MD, PhD

February 10, 2026 · 58 min

Show notes

Ben welcomes psychiatrist Dr. Mike Halassa back to the podcast to discuss the shifting landscape of inpatient schizophrenia treatment. An early adopter of Cobenfy, Dr. Halassa shares real-world insights from his research published in Nature Mental Health in this conversation that bridges technical neuroscience with the high-stakes reality of managing acute psychiatric crises.

The discussion focuses on Cobenfy’s muscarinic mechanism, the first novel approach to psychosis in seventy years. Dr. Halassa details his "dose-sparing" strategy, reducing reliance on traditional D2 blockers and their metabolic burdens, and he shares case studies of treatment-resistant patients who succeeded on this agent after clozapine failed. Finally, Ben and Dr. Halassa explore functional recovery, precision psychiatry, and the empathic connection required to treat society's most vulnerable individuals.

Episode Highlights:

00:00 - Welcoming Back Dr. Mike Halassa

01:46 - ‘Spending a Day in Someone Else’s Brain’

04:21 - Empathy, Parenting, and Staying Grounded in Psychiatry

06:37 - Why Inpatient Psychiatry Works: Acuity, Speed, and Team-Based Care

09:31 - Evaluating Acute Psychosis: Intake, Chronicity, and Treatment Decisions

12:46 - Discovering XT as the First Novel Schizophrenia Mechanism in Decades

16:19 - A Remarkable XT Case Study

23:26 - XT Dosing Tolerability and Early Clinical Results

30:15 - From Observation to Evidence: Identifying XT Response Patterns

35:12 - Testing Negative Symptoms in Real Time on the Inpatient Unit

40:33 - XT vs D2 Blockers for Positive and Negative Symptom Control

50:28 - Redefining Success in Schizophrenia Through Functional Recovery

54:15 - The Future of Precision Psychiatry and Treating the Whole Person

56:42 - Up Next: Dr. Avi Bhar

Key Takeaways:

"Inpatient psychiatry demands quick thinking and rapid decisions. It's a critical care type environment."

"I find my kids keep me grounded and empathetic. They're my window into empathy."

"XT offers a fundamentally different way of engaging the system. It's not just another antipsychotic."

"Seeing patients become more socially connected on XT is remarkable. It's a new light in their eyes."

"Negative symptoms have been intractable. XT offers hope for functional recovery."

"The multidisciplinary team is crucial in schizophrenia care. It requires coordination and dedication."

"XT allows for dose sparing of traditional antipsychotics, potentially reducing side effects."

"We must aspire to help patients engage with life fully, beyond just managing symptoms."

Links:

Full transcript and show notes: https://www.psychiatrist.com/jcp/ep8-early-use-xanomeline-trospium-michael-halassa/

Journal of Clinical Psychiatry: psychiatrist.com/jcp/

Dr. Halassa’s Substack: michaelhalassa.substack.com

The Halassa Lab: https://halassalab.tufts.edu/

Preliminary real-world predictors of response to muscarinic targeting in psychosis: https://www.nature.com/articles/s44220-025-00529-w

Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report: https://pubmed.ncbi.nlm.nih.gov/41201439/

All episodes of The Journal of Clinical Psychiatry Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.